| Literature DB >> 27067082 |
Zhaoying Yang1,2, Le Zhang1,2, Stefano Serra2,3, Calvin Law4,5, Alice Wei2,5, Tracy L Stockley2,3, Shereen Ezzat2,6, Sylvia L Asa7,8,9.
Abstract
Neuroendocrine tumors (NETs) are increasing in incidence yet the cause of these tumors remains unknown. Familial associations have shed light on the genetic basis of some of these tumors, but sporadic tumors seem to have primarily epigenetic dysregulation. The rarity of cell lines and animal models has been a barrier to studies of treatment modalities. We set out to develop a xenograft model of gastrointestinal NETs. Primary human NETs were collected at the time of surgery under sterile conditions and xenografted into the flanks of immunodeficient mice. Tumor growth was measured and when tumors reached 1500 mm(3), they were excised and half was re-xenografted through multiple generations. The other half was bisected; a part was frozen and a part was fixed for morphologic and immunohistochemical characterization as well as molecular validation of fidelity of a successful xenograft. Of 106 human NETs, seven were successfully engrafted of which only one tumor was successfully propagated for eight passages. Two years later, the tumor retains its neuroendocrine features and similarity to the original primary human tumor. It has retained expression of keratin as well as chromogranin A reactivity. The establishment of a NET xenograft provides a model for further study of the biological behavior of these tumors and can be used to examine the in vivo effects of various medical and targeted radiotherapeutic agents on tumor growth.Entities:
Keywords: Cell lines; Mouse model; Neuroendocrine tumor; Xenograft
Mesh:
Year: 2016 PMID: 27067082 DOI: 10.1007/s12022-016-9429-4
Source DB: PubMed Journal: Endocr Pathol ISSN: 1046-3976 Impact factor: 3.943